Publications by authors named "Stephanie Merhand"

8 Publications

  • Page 1 of 1

Impact of Atopic Dermatitis in Adolescents and their Parents: A French Study.

Acta Derm Venereol 2020 Oct 20;100(17):adv00294. Epub 2020 Oct 20.

Department of Dermatology, Hôpital Henri Mondor, FR-94000 Creteil, France.

Atopic dermatitis has a negative impact on quality of life in patients and their families. However, there have been very few studies of the impact of atopic dermatitis on adolescents and their relatives. The objective of this study was to evaluate the impact of atopic dermatitis in the daily lives of adolescents between 12 and 17 years of age in the French population and to assess the burden of the disease on their families. Quality of life was measured in 399 parents of adolescents with atopic dermatitis and in the adolescents themselves. Impairment of quality of life in the adolescents was associated with disease severity. Moreover, in children aged 12-14 years, quality of life was worse with increasing age, with decreasing disease duration, and when parents had atopic dermatitis. In children aged 15-17 years quality of life was worse when the parent who answered the questionnaire was male and when the parent was < 45 years old. The burden of atopic dermatitis was higher in parents of older children, in parents with children with higher disease severity, with shorter disease duration, in male parents, and in parents aged <45 years. The burden of atopic dermatitis in adolescents and their parents is considerable and should be taken into account in the management of atopic dermatitis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3653DOI Listing
October 2020

Perceived clinical severity of atopic dermatitis in adolescents: Comparison between patients' and parents' evaluation.

J Am Acad Dermatol 2021 Jan 15;84(1):164-165. Epub 2020 Apr 15.

Public Health, Hôpital Necker Enfants Malades, Paris, France; European Market Maintenance Assessment, Vincennes, France; Maison de la Dermatologie, Société Française des Sciences Humaines sur la Peau (SFSHP), Paris, France. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.04.037DOI Listing
January 2021

Building a scale for measuring burden of hand eczema: BoHEM.

J Am Acad Dermatol 2019 06 23;80(6):1784-1785. Epub 2018 Dec 23.

FIMARAD (Filière de santé Maladies rares: maladies rares en dermatologie), Paris, France; European Market Maintenance Assessment, Fontenay sous-Bois, France. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.12.036DOI Listing
June 2019

Characteristics of Pruritus in Relation to Self-assessed Severity of Atopic Dermatitis.

Acta Derm Venereol 2019 Mar;99(3):279-283

Department of Dermatology, University Hospital, Brest, France.

The objective of this study was to explore characteristics of pruritus in atopic dermatitis (AD) in relation to the severity of AD. A web-questionnaire was used, which included the Patient-Oriented SCORing Atopic Dermatitis index, the 5-D itch scale and the Brest questionnaire. A total of 170 participants were included (86.5% women, mean age 30.9 years). Severity of AD was mild for 8.2% of patients, moderate for 38.2% and severe for 53.5%. Mean 5-D itch scale was 13.2. The mean intensity of pruritus was 5.8, and mean sleep loss was 4.7 (from 0 to 10). The participants frequently described burning (61.8%) and stinging (58.8%); these symptoms suggest a neuropathic component. Pruritus was worse in severe AD compared with moderate AD, exhibiting a higher impact on sleep and more associated symptoms. The majority of participants reported sleep disturbance as a result of pruritus. The characteristics of pruritus varied depending on the severity of AD.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3053DOI Listing
March 2019

[Living with atopic dermatitis].

Rev Prat 2017 04;67(4):405-406

Pharmacie de Bois Luzy, Marseille, France, membre de l'Association française de l'eczéma.

View Article and Find Full Text PDF

Download full-text PDF

Source
April 2017

Atopic Dermatitis Burden Scale for Adults: Development and Validation of a New Assessment Tool.

Acta Derm Venereol 2015 Jul;95(6):700-5

Department of Dermatology, University of Bordeaux, FR-33000 Bordeaux, France.

Atopic dermatitis (AD) occurs in approximately 2-3% of adults. The aim of this study was to develop and validate the self-administered Atopic Dermatitis Burden Scale for Adults (ABS-A). Patients were enrolled consecutively from those attending the Station Thermale Avène for a diagnosis of AD. ABS-A was developed using standard methodology, and consisted of 3 phases: exploratory, development, and validation. Internal consistency (Cronbach's α), concurrent validity (Spearman's correlation between ABS-A, SF-12 and Dermatology Life Quality Index [DLQI)]), and discriminant validity, were analysed. A total of 128 adults (68.8% females) completed the ABS-A, consisting of 18 items grouped into 4 domains. ABS-A showed good internal coherence (Cronbach's α, 0.89) and was correlated with both SF-12 components [r = -0.36, p < 0.0001 (Physical); r = -0.52, p < 0.0001 (Mental)] and DLQI (r = 0.78; p < 0.0001). The ABS-A score varied significantly according to AD severity. To our knowledge, ABS-A is the first specific tool for assessing AD burden in adult patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-1945DOI Listing
July 2015

Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting.

Allergy 2012 Sep 30;67(9):1111-7. Epub 2012 Jul 30.

Centre for Evidence-Based Healthcare, University Hospital Dresden, Germany.

The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a major obstacle to practising evidence-based dermatology. The Harmonising Outcome Measures for Eczema (HOME) initiative is an international multiprofessional group dedicated to atopic eczema outcomes research. In June 2011, the HOME initiative conducted a consensus study involving 43 individuals from 10 countries, representing different stakeholders (patients, clinicians, methodologists, pharmaceutical industry) to determine core outcome domains for atopic eczema trials, to define quality criteria for atopic eczema outcome measures and to prioritize topics for atopic eczema outcomes research. Delegates were given evidence-based information, followed by structured group discussion and anonymous consensus voting. Consensus was achieved to include clinical signs, symptoms, long-term control of flares and quality of life into the core set of outcome domains for atopic eczema trials. The HOME initiative strongly recommends including and reporting these core outcome domains as primary or secondary endpoints in all future atopic eczema trials. Measures of these core outcome domains need to be valid, sensitive to change and feasible. Prioritized topics of the HOME initiative are the identification/development of the most appropriate instruments for the four core outcome domains. HOME is open to anyone with an interest in atopic eczema outcomes research.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1398-9995.2012.02874.xDOI Listing
September 2012